Literature DB >> 9720634

Behavioural pharmacological characteristics of honokiol, an anxiolytic agent present in extracts of Magnolia bark, evaluated by an elevated plus-maze test in mice.

H Kuribara1, W B Stavinoha, Y Maruyama.   

Abstract

Honokiol, a neolignane derivative of Magnolia bark, has central depressant action and, at much lower doses, anxiolytic activity. We have investigated the characteristics of the behavioural effects of honokiol by means of an elevated plus-maze test. In the plus-maze test a single oral dose of 20 mg kg(-1) honokiol significantly prolonged the time spent in the open arms of the maze, suggesting anxiolytic effect. Moreover, when honokiol was administered daily for seven days and the plus-maze test was conducted 3 or 24 h after the last administration, significant prolongation of the time in the open arms was manifested even for doses of 0.2 mg kg(-1). The maximum effect was observed for doses of 0.5 mg kg(-1). Honokiol at any dose in both single and repeated administration schedules caused neither change in motor activity nor disruption of traction performance. Orally administered diazepam, 0.5-2 mg kg(-1), caused dose-dependent prolongation of the time spent in the open arms of the maze with a significant increase in motor activity at 1 mg kg(-1), and dose-dependent disruption of traction performance. The changes in the plus-maze performance after treatment for seven days with 0.2 mg kg(-1) honokiol and after a single treatment with 1 mg kg(-1) diazepam were almost equivalent. The effect of honokiol (0.2 mg kg(-1), treatment for seven days) was inhibited by subcutaneous flumazenil (0.3 mg kg(-1)) and (+)-bicuculline (0.1 mg kg(-1)) and by intraperitoneal CCK-4 (50 microg kg(-1)) and caffeine (30 mg kg(-1)). The anxiolytic effect of diazepam (1 mg kg(-1)) was also inhibited by flumazenil and bicuculline. However, the combined administration of diazepam with caffeine enhanced the effect, and diazepam completely reversed the effect of CCK-4. These results suggest that, in contrast with diazepam, honokiol selectively induces an anxiolytic effect with less liability of eliciting motor dysfunction and sedation or disinhibition. The combined effects of the drug also revealed that the mechanism of anxiolytic effect of honokiol is partially different from that of diazepam.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9720634     DOI: 10.1111/j.2042-7158.1998.tb07146.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  21 in total

1.  Honokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in mice.

Authors:  Wei-Min Qu; Xiao-Fang Yue; Yu Sun; Kun Fan; Chang-Rui Chen; Yi-Ping Hou; Yoshihiro Urade; Zhi-Li Huang
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

2.  The natural products magnolol and honokiol are positive allosteric modulators of both synaptic and extra-synaptic GABA(A) receptors.

Authors:  Mikhail Alexeev; Denise K Grosenbaugh; David D Mott; Janet L Fisher
Journal:  Neuropharmacology       Date:  2012-03-12       Impact factor: 5.250

Review 3.  Plant natural products: from traditional compounds to new emerging drugs in cancer therapy.

Authors:  L Ouyang; Y Luo; M Tian; S-Y Zhang; R Lu; J-H Wang; R Kasimu; X Li
Journal:  Cell Prolif       Date:  2014-12       Impact factor: 6.831

4.  Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.

Authors:  Kenji Ishitsuka; Teru Hideshima; Makoto Hamasaki; Noopur Raje; Shaji Kumar; Hiromasa Hideshima; Norihiko Shiraishi; Hiroshi Yasui; Aldo M Roccaro; Paul Richardson; Klaus Podar; Steven Le Gouill; Dharminder Chauhan; Kazuo Tamura; Jack Arbiser; Kenneth C Anderson
Journal:  Blood       Date:  2005-05-03       Impact factor: 22.113

5.  Effects of magnolol and honokiol derived from traditional Chinese herbal remedies on gastrointestinal movement.

Authors:  Wei-Wei Zhang; Yan Li; Xue-Qing Wang; Feng Tian; Hong Cao; Min-Wei Wang; Qi-Shi Sun
Journal:  World J Gastroenterol       Date:  2005-07-28       Impact factor: 5.742

6.  Magnolol Protects against MPTP/MPP(+)-Induced Toxicity via Inhibition of Oxidative Stress in In Vivo and In Vitro Models of Parkinson's Disease.

Authors:  Akiko Muroyama; Aya Fujita; Cheng Lv; Shota Kobayashi; Yoshiyasu Fukuyama; Yasuhide Mitsumoto
Journal:  Parkinsons Dis       Date:  2012-05-08

7.  Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model.

Authors:  Xianhuo Wang; Xingmei Duan; Guangli Yang; Xiaoyan Zhang; Linyu Deng; Hao Zheng; Chongyang Deng; Jiaolin Wen; Ning Wang; Cheng Peng; Xia Zhao; Yuquan Wei; Lijuan Chen
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

8.  Psychological interventions in the management of common skin conditions.

Authors:  Philip D Shenefelt
Journal:  Psychol Res Behav Manag       Date:  2010-03-26

9.  Hangekobokuto (Banxia-houpo-tang), a Kampo Medicine that Treats Functional Dyspepsia.

Authors:  Tetsuro Oikawa; Go Ito; Takayuki Hoshino; Hidehiko Koyama; Toshihiko Hanawa
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-04       Impact factor: 2.629

10.  Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial.

Authors:  Douglas S Kalman; Samantha Feldman; Robert Feldman; Howard I Schwartz; Diane R Krieger; Robert Garrison
Journal:  Nutr J       Date:  2008-04-21       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.